Analysis of 5'-deoxy-5-fluorouridine and 5-fluorouracil in human plasma and urine by high-performance liquid chromatography.
A relatively simple and sensitive high-performance liquid chromatographic (HPLC) method is described for measuring the two anticancer drugs 5'-deoxy-5-fluorouridine (5'dFUR) and 5-fluorouracil (5-FU) in human plasma and urine. The procedure for plasma includes solvent extraction using ethyl acetate-isopropyl alcohol (85:15) followed by silica gel column chromatography to separate these compounds from constituents normally occurring in plasma. The analysis by reversed-phase HPLC is performed on a phenyl column using an aqueous mobile phase with ultraviolet detection (280 nm). The overall recovery from plasma was 61% and 65% for 5'dFUR and 5-FU, respectively. The sensitivity limit of the assay for both compounds was 50 ng/ml of plasma. Analysis of these compounds in urine did not require the silica column chromatography isolation step.
Schaaf
L J
LJ
Ferry
D G
DG
Hung
C T
CT
Perrier
D G
DG
Edwards
I R
IR
D002851:Chromatography, High Pressure Liquid; D005467:Floxuridine / Q000032:analysis* / Q000097:blood / Q000652:urine; D005472:Fluorouracil / Q000032:analysis* / Q000097:blood / Q000652:urine; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007700:Kinetics; D013056:Spectrophotometry, Ultraviolet
D005467:Floxuridine; D005472:Fluorouracil; C025034:doxifluridine